People

BioSpace spoke to Aurika Savickaite, RN, MSN, to learn more about the ventilator helmet initiative, NIV helmets, and how they can be used during this coronavirus pandemic.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 30, 2020.
Disgraced pharmaceutical executive Martin Shkreli wants out of prison to help research a treatment for COVID-19, but federal prosecutors want him to remain behind bars for the duration of his sentence for fraud.
“Although a 31% improvement doesn’t seem like a knockout 100%, it is a very important proof of concept,” said Anthony S. Fauci, director of NIAID. “What it has proven is that a drug can block this virus. This will be the standard of care.”
ADC Therapeutics SA, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced the appointment of Victor Sandor, M.D., to its Board of Directors.
Recent reports revealed that the infection rates between adults and children were similar, but men are more likely to exhibit severe symptoms. The report also highlights the importance of contact tracing to help mitigate infection rates.
The study was run by Johns Hopkins University and Geisinger Health, testing more than 10,000 women with no previous history of cancer.
Expectations that a vaccine against COVID-19 will be available within a year’s time are mixed, based on recent surveys conducted by BioSpace, as well as the analytics company GlobalData.
Writing in The Motley Fool, Billy Duberstein, the portfolio manager at Stone Oak Capital, pointed at these two treatment options as potential weapons against the pandemic.
Saniona, a clinical stage biopharmaceutical company focused on rare diseases, announced that it has appointed Rudolf Baumgartner, M.D., as Chief Medical Officer and Head of Clinical Development starting on May 1, 2020.
PRESS RELEASES